Genedrive® MT-RNR1 ID Kit Product – Video

World’s first point of care genetic test used to influence neonatal management in an acute setting and reduce aminoglycoside-induced hearing loss​​

Prevention – reduces the likelihood of aminoglycoside-induced hearing loss

Rapid results – point-of-care genetic test yields results in 30 minutes

Simple to use – by healthcare professionals with minimal training

An in vitro diagnostic (IVD) molecular assay for use in human buccal cells

The Genedrive® MT-RNR1 ID Kit used in conjunction with the Genedrive® System provides an automated result of an individual’s MT-RNR1 m.1555 variant status to inform the clinician ahead of antibiotic treatment decisions. ​

The Genedrive® MT-RNR1 ID Kit is intended to be used by healthcare professionals within a near patient setting.​

The Genedrive® System is a compact benchtop system that provides rapid nucleic amplification, detection and result reporting without the need for data interpretation

  • Reduces the likelihood of aminoglycoside induced hearing loss
  • Provides a clear patient benefit by informing the clinician ahead of prescription
  • Rapid genetic screening prior to aminoglycoside treatment

Individuals with the MT-RNR1 m.1555A>G variant develop profound irreversible hearing loss if exposed to aminoglycoside – population-based studies estimate prevalence of 1:500 (0.2%)

  • Single use, cost effective test for use by healthcare professionals with minimal training
  • Easy adoption into existing neonatal admissions process to inform clinicians ahead of antibiotic treatment decisions
  • Non-invasive test using buccal swabs from the inner cheek

First NHS Deployments of Genedrive System for AIHL



Linking Shareholders and Executives :Share Talk

If anyone reads this article found it useful, helpful? Then please subscribe or follow SHARE TALK on our Twitter page for future updates. Terms of Website Use All information is provided on an as-is basis. Where we allow Bloggers to publish articles on our platform please note these are not our opinions or views and we have no affiliation with the companies mentioned

Weekly Newsletter

Sign up to receive exclusive stock market content in your inbox, once a week.

We don’t spam! Read our privacy policy for more info.